Compare Heron Therapeutics Inc (HRTX) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Morgan Stanley — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Morgan Stanley trades at $215.92 (market cap $331.60B). The key difference: Morgan Stanley is far larger — about 3625.6× Heron Therapeutics Inc's market cap, and Morgan Stanley pays a 2.18% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MS | |
|---|---|---|
Market Cap | $91.46M | $331.60B |
Sector | Health | Financials |
52-Week High | $1.96 | $228.42 |
52-Week Low | $0.39 | $139.09 |
Enterprise Value | $189.36M | — |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Morgan Stanley (MS) trades at $215.48, down 1.33% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $66.0B in 2025, with net income reaching $16.9B and a profit margin of 25.6%. The stock has beaten earnings estimates for three consecutive quarters, and analysts maintain a consensus buy rating with a $241.36 price target. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook for MS is positive, driven by earnings momentum and strategic initiatives like AI adoption and high-profile IPOs. Risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to the consensus target, but investors should monitor execution on growth initiatives and macroeconomic impacts on financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
